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Introduction: To assess the feasibility, safety and local tumor con-
trol of cryoablation for treatment of pulmonary metastases.
Materials and Methods: This Health Insurance Portability and 
Accountability Act (HIPAA) compliant, IRB-approved, multi-
center, prospective, single arm study included 40 patients with 
60 lung metastases treated during 48 cryoablation sessions, with 
currently a minimum of 12 months of follow-up. Patients were 
enrolled according to the following key inclusion criteria: 1 to 5 
metastases from extrapulmonary cancers, with a maximal diam-
eter of 3.5 cm. Local tumor control, disease-specific and overall 
survival rates were estimated using the Kaplan–Meier method. 
Complications and changes in physical function and quality of life 
were also evaluated using Karnofsky performance scale, Eastern 
Cooperative Oncology Group performance status classification, 
and Short Form-12 health survey.
Results: Patients were 62.6 ± 13.3 years old (26–83). The most com-
mon primary cancers were colon (40%), kidney (23%), and sarcomas 
(8%). Mean size of metastases was 1.4 ± 0.7 cm (0.3–3.4), and metas-
tases were bilateral in 20% of patients. Cryoablation was performed 
under general anesthesia (67%) or conscious sedation (33%). Local 
tumor control rates were 56 of 58 (96.6%) and 49 of 52 (94.2%) at 6 and 
12 months, respectively. Patient's quality of life was unchanged over the 
follow-up period. One-year overall survival rate was 97.5%. The rate 
of pneumothorax requiring chest tube insertion was 18.8%. There were 
three Common Terminology Criteria for Adverse Events grade 3 proce-
dural complications during the immediate follow-up period (pneumo-
thorax requiring pleurodesis, noncardiac chest pain, and thrombosis of 
an arteriovenous fistula), with no grade 4 or 5 complications.
Conclusion: Cryoablation is a safe and effective treatment for pulmo-
nary metastases with preserved quality of life following intervention.
Key words: Lung metastasis, Cryoablation, Percutaneous ablation, 
Tumor control, Safety.
(J Thorac Oncol. 2015;10: 1468–1474)
Lung metastases in patients with oligometastatic disease are managed with surgery, stereotactic body radiation 
therapy (SBRT), and ablative therapies.1 Surgical resec-
tion is the standard of care for these patients when possi-
ble.2 Surgery is not an option for many patients because of 
advanced age, comorbidities, limited respiratory function, 
prior pulmonary resection, or surgery refusal.3,4 For these 
patients, image-guided ablation and radiation therapy are 
increasingly offered as alternative therapies.3–9 Early reports, 
including case series and small clinical trials, demonstrate 
the potential of radiofrequency ablation (RFA), microwave 
ablation, and cryoablation for treatment of pulmonary 
tumors.5,10–18 Cryoablation uniquely offers visibility of the 
ablation margin with cross-sectional imaging due to forma-
tion of an interstitial infiltrate or visible ice, which defines 
the ablation zone and allows for complete tumor ablation 
while avoiding adjacent normal tissues and can be used 
along the pleura without procedural pain.15,19
Limited case reports and series of the use of percutane-
ous cryoablation for treatment of pulmonary metastases are 
encouraging,18 although data are limited to characterizing the 
safety of treatment. The objectives of this prospective clini-
cal trial were to assess the feasibility and safety of cryoabla-
tion and local tumor control of lung metastases smaller than 
3.5 cm. This report represents the first prospective clinical trial 
for the use of cryoablation for early efficacy of treatment of 
pulmonary metastases.
Evaluating Cryoablation of Metastatic Lung Tumors in 
Patients—Safety and Efficacy
The ECLIPSE Trial—Interim Analysis at 1 Year
Thierry de Baere, MD,*† Lambros Tselikas, MD,*† David Woodrum, MD, PhD,‡ Fereidoun Abtin, MD,§ 
Peter Littrup, MD,║ Frederic Deschamps, MD,*† Robert Suh, MD,§ Hussein D. Aoun, MD,║  
and Matthew Callstrom, MD, PhD‡
DOI: 10.1097/JTO.0000000000000632.
Copyright © 2015 by the International Association for the Study of Lung 
Cancer This is an open-access article distributed under the terms of the 
Creative Commons Attribution-Non Commercial-No Derivatives License 
4.0 (CCBY-NC-ND), where it is permissible to download and share the 
work provided it is properly cited. The work cannot be changed in any way 
or used commercially.
ISSN: 1556-0864/15/1010-1468
*Department of Radiology, Gustave Roussy—Cancer Campus, Villejuif, France; 
†Université Paris-Sud XI, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin 
Bicêtre, France; ‡Department of Radiology, Mayo Clinic and Mayo Medical 
School, Rochester, Minnesota; §Department of Radiological Sciences, 
Ronald Reagan UCLA Medical Center, Los Angeles, California; and 
║Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.
This study was supported by Galil Medical. This study was not supported by 
the NIH, HHMI, or tobacco industry.
Disclosure: All authors have received research grants from Galil during the 
Eclipse study. Dr. Aoun, Dr. Callstrom, Dr de Baere, and Dr. Littrup, 
have received manuscript writing grants from Galil. Dr. de Baere is con-
sultant for Covidien, Dr. Deschamps for Medtronic, and Dr. Callstrom 
for Medtronic, Covidien, and Endocare.
Address for correspondence: Thierry de Baere, MD, Interventional Radiology 
Department, Gustave Roussy—Cancer Campus, 114 rue Edouard Vaillant, 
94805 Villejuif, France. E-mail: thierry.debaere@gustaveroussy.fr.
ORIGINAL ARTICLE
Copyright © 2015 by the International Association for the Study of Lung Cancer
1469Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 10, October 2015 Cryoablation: An Effective Treatment for Lung Metastases
MATERIALS AND METHODS
This Health Insurance Portability and Accountability Act 
(HIPAA) compliant, single arm, phase 1 multicenter prospec-
tive study was approved by the institutional review board for 
each center, and written consent was obtained from all patients.
Between January 2012 and March 2013, 40 patients 
qualified for the trial and underwent cryoablation for total of 
60 metastases (Tables 1 and 2).
Patients were enrolled prospectively at four hospi-
tal centers (one in Europe and three in the United States). 
Inclusion criteria were age 18 years old or more, pulmonary 
metastatic disease, Eastern Cooperative Oncology Group 
(ECOG) score20 of 0–2, Karnofsky performance scale (KPS) 
score21 greater than or equal to 60, a maximum of three metas-
tases unilaterally and total of five bilaterally, with a size of the 
largest metastasis of 3.5 cm or smaller on a computed tomog-
raphy (CT) scan obtained within 4 weeks before the proce-
dure, and no previous targeted local therapy to the currently 
targeted lung metastasis. All percutaneous cryoablations were 
reviewed and approved by an oncologist, a surgeon, and an 
interventional radiologist at the institution where the proce-
dure was performed. Exclusion criteria included platelet count 
less than 50,000/mm3 and International Normalized Ratio 
greater than 1.5, evidence of infection or neutropenia (abso-
lute neutrophil count of less than 1000/ml).
Metastases to the lungs or pleura were either confirmed 
by biopsy or deemed eligible as new or growing nodules on 
sequential imaging (CT or positron emission tomography/CT) 
in patients with an already pathologically proven primary cancer.
Between January 2012 and March 2013, 40 patients 
qualified for the trial and underwent cryoablation for total of 
60 metastases (Tables 1 and 2).
Cryoablation Procedure
Ablation was performed under general anesthesia or 
conscious sedation based on the preoperative anesthesiologist 
evaluation and investigator preferences at each center.
Cryoablation needles, 1.5 mm or 2.4 mm in diameter 
(17 and 13 gauge), provided by Galil Medical, Inc. (Arden 
Hills, MN) were placed under CT-scan guidance (Fig. 1) stra-
tegically to cover the tumor with an adequate margin lethal ice. 
Number, type, and configuration of the needles were based on 
the necessity to maintain a distance between adjacent cryoab-
lation needles (less than or equal to 15 mm) and not more than 
10 mm from the tumor margin while avoiding or displacing 
adjacent normal anatomical structures.
Cryoablation was performed applying a three-cycle 
freeze–thaw phase protocol. The times for each phase were 
recorded and varied as a function of the size of the tumor (tar-
get times were 3-min freeze, 3-min thaw, 8-min freeze, 5-min 
stick, 8-min freeze followed by active thawing). Each proce-
dure was monitored with noncontrast CT imaging at 3 to 5 
minutes intervals to visualize the evolving ablation zone with 
the goal of achieving a circumferential margin beyond the 
tumor of 5 mm. After cryoablation needle(s) were removed, 
CT images were obtained to assess the overall ablation zone 
and any potential complications.
Follow-up
Patient-specific follow-up for the study was done within 
the first week, at 1, 3, 6, and 12 months. Within 1 week of a 
single procedure or the last of multiple procedures, patients 
had chest X-ray or a CT without intravenous contrast to 
assess for early complications. Patients were clinically evalu-
ated at 1 month from the last ablation to assess safety of the 
TABLE 1.  Baseline Patient and Lesion Characteristics
Characteristic Value
Age, yra (±SD) 62.6 ± 13.3
Gender
  Male 24 (60%)
  Female 16 (40%)
BMI (±SD) 26.7 ± 5.3
Primary tumor type histology
  Colorectal 17 (42.5%)
  Renal cell carcinoma 7 (17.5%)
  Sarcoma 4 (10%)
  Other 12 (30%)
Previous focal treatments for other lung metastases
  Radiation surgery 5 (13%)
  Surgery 14 (35%)
  Cryoablation 3 (8%)
  RFA 7 (18%)
  Microwave 2 (5%)
Tumor characteristics
  Mean tumor diameter (cm) 1.4 ± 0.7 (range, 0.3–3.4)
  Tumor size (cm)
   0.3–1.0 18 (30%)
   1.1–2.0 30 (50%)
   2.1–3.0 11 (18.3)
   ≥3.1 1 (1.7%)
  Number of tumors treated per patient 1.8 ± 1.0 (range, 1.0–4.0)
  Tumor distribution
   Unilateral 32 (80%)
   Bilateral 8 (20%)
aForty-eight cryoablation procedures.
TABLE 2.  Cryoablation Procedure Characteristics
Characteristic Value
Procedure time (min)a 101.2 ± 38.7
Freeze duration per tumorb (min) 21.2 ± 4.6
Anesthesia
  General 32 (67%)
  Conscious sedation 15 (31%)
  Regional 1 (2%)
Number of cryoablation needles per 
tumor (±SD)
1.6 ± 0.9
Mean hospital stay 1 day (range, 0–4), 25.3 ± 21 hr (7–99)
aForty-eight cryoablation procedures.
bSixty tumors, typically three freeze cycles.
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procedure and its impact on quality of life. Follow-up at 3, 6, and 
12 months included clinical examination, chest CT with or 
without intravenous contrast material (Fig. 2), and quality of life 
evaluation. Follow-up will continue annually through 5 years.
Data Collection
Data were collected at each institution, anonymized 
and centralized to a web-based electronic data capture system 
(TrackIt2K, Acumen Healthcare Solutions, LLC, Plymouth, 
MN), compliant with FDA 21 CFR Part 11 guidance. Collected 
data included patient demographics, primary cancer histology, 
prior cancer treatment, number of metastases, tumor location, 
and maximal tumor dimensions. Procedural times, anesthesia 
type, the number and type of cryoablation needles, procedural 
complications and interventions, and the length of hospital stay 
were also recorded.
Treatment Outcome Measures
Technical success for each treated tumor was defined as 
a zone of ground glass opacity, or visible ice encompassing 
the targeted tumor with at least a 5-mm circumferential abla-
tive margin on CT at end of the cryoablation. To be considered 
a technical success in each patient, all targeted tumors had to 
meet defined postablation technical success criteria.
Local tumor control assessment was based on imaging 
measures and ablation zone enhancement patterns at 6 and 
12 months, using the appearance of the ablation zone at 
3 months as comparative baseline. The 3-month follow-up 
imaging was selected to represent the baseline scan, as the 
ablation zone is larger than the targeted tumor. Assessment 
of tumor progression or incomplete ablation was based on 
changes in size and contrast enhancement relative to the 3-month 
baseline. Tumor response was calculated using the sum of the 
largest diameter of ablation zones and compared with baseline 
scan at 3 months. “Complete” response was defined as reduc-
tion of 75%, “partial” response as 30% to 75% decrease in size 
of the ablation zone, “stable disease” when there was less than 
30% decrease and less than 20% increase in the size of the abla-
tion zone, and “local failure” when an increase of greater than 
20% compared with the smallest diameter (nadir) of the abla-
tion zone or the appearance of nodular enhancement.
Time to tumor progression was defined as the time from 
cryoablation procedure to local failure.
Distant tumor progression was defined as the appear-
ance of distant metastatic disease outside of the treatment 
area, either in the lung or outside the lung.
Disease specific survival and overall survival rates were 
calculated from the day of the ablation to time of death related 
to cancer and related to any cause, respectively.
Safety and Procedural Tolerance Assessment
Adverse events that occurred within 30 days of the pro-
cedure were reported considering causality and severity and 
were graded in accordance with the Common Terminology for 
Adverse Criteria for Adverse Events (CTCAE version 4.0) of 
the National Cancer Institute.22 Subsequent hospital admis-
sion and surgical interventions were also recorded.
Changes in physical function and quality of life over 
time included physical performance (ECOG and KPS) and 
quality of life employing Short Form-12 (SF-12) assessment 
at baseline and during follow-up.23
Statistical Analysis
All subjects treated were included in the analyses (per 
protocol). Continuous variables are expressed as mean, stan-
dard deviation, number of patients, median, minimum, and 
maximum. Categorical variables including efficacy outcomes 
and adverse events are summarized by frequencies and per-
centages of patients in each category.
Survival rates are analyzed using Kaplan–Meier meth-
odology. ECOG, Karnofsky, and SF-12 analyses used repeated 
measures analysis of variance models to examine differences. 
SAS version 9.3 (SAS Institute, Cary, NC) statistical software 
was used for analyses. P values less than 0.05 were considered 
as statistically significant.
RESULTS
Patients and Tumors
Patient and tumor characteristics are summarized in 
Table 1. Among the 40 enrolled patients, colorectal origin was 
the most frequent cancer, accounting for 40% of metastases. 
Thirty of 40 (75%) patients had prior focal treatment for other 
lung metastases but without prior treatment to the targeted lung 
metastases on this study. Seven of the 40 (18%) patients received 
systemic chemotherapy concurrently or after the cryoablation 
treatment. No patients received radiation therapy to the targeted 
tumors in this study after cryoablation. Three of 60 tumors (5%) 
had pleural contact, and no tumors had hilar involvement.
FIGURE 1.  Percutaneous cryoablation under computed tomog-
raphy (CT)-scan guidance. CT-scan images of the chest without 
contrast obtained before (A and B) and during (C and D) the 
cryoablation from a 71-year-old patient with right lower lobe 
lung metastases from a colon adenocarcinoma.
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Cryoablation
A total of 60 thoracic metastases were treated during 
48 procedures in 40 patients. Treatment of bilateral disease 
on the same day was not allowed per protocol. The mean 
number of cryoablation needles used per procedure was 
1.6 (range, 1–5). For tumors less than 2.0 cm in diameter, 
a mean of 1.7 probes with a range of 1 to 3 probes were 
used in treatment. For tumors larger than 2.0 cm in diam-
eter, a mean of 2.3 probes with a range of 1 to 5 probes 
were used in treatment. Fifty-three of 60 (88%) tumors were 
treated with three freeze cycles, two tumors (3%) with two 
freeze cycles, and five (8%) tumors with four freeze cycles. 
Mean procedure time was 101.2 minutes (±38.7) includ-
ing anesthesiology management, cryoprobe placement, 
ablation time, and postprocedural CT evaluation (Table 2). 
Immediate technical success was obtained in all 40 patients 
(100%) and 60 tumors (100%).
Treatment Efficacy
Primary efficacy is shown in Table 3. Thirty-five of 40 
(90%) patients were included in the follow-up analysis. Of 
the five patients not available for the 12-month analysis, one 
patient had progression of disease outside the lung, which pre-
cluded further follow-up beyond 6 months, one patient had an 
unrelated death 5 months after treatment, one patient com-
pleted the 12-month visit but did not have imaging conducted, 
and two patients were lost to follow-up. Overall local tumor 
control after ablation at the 12-month analysis, for combined 
stable disease, partial, and complete response, was seen in 49 
of 52 metastases (94.2%) and 32 of 35 patients (91.4%). Three 
of 52 metastases (5.8%) had local failure observed at 6 and 
12 months with increasing size of the ablation zone. There 
was no significant difference in rate of tumor progression, or 
incomplete ablation, as a function of original treated tumor 
diameter (p = 0.41). For the remainder of the treated tumors 
that were followed in this study, no enlargement of the abla-
tion zone or appearance of nodular enhancement were dem-
onstrated during the 12-month follow-up (Fig. 2). Two of the 
three local progressions could be retreated with focal therapy 
(one cryoablation and one radiofrequency). The remaining 
local failure observed at 6 months was associated with wide-
spread progression of metastatic disease, for which the patient 
received immunotherapy.
At 12 months, there was evidence of additional meta-
static disease in 14 of 35 evaluable patients (40%), with a 
mean time to new metastases postcryoablation treatment of 
10.7 months (SD ± 3.6). Fifteen of the 40 patients (38%) 
received new therapies during the study. Systemic treatment 
for diffuse metastatic disease (chemotherapy: n = 7 and immu-
notherapy: n = 1) was administrated to eight patients (20%), 
and 10 patients (25%) received other focal therapies for new 
TABLE 3.  Primary Efficacy Per Metastases
6-mo Metastases = 58 12-mo Metastases = 52
Complete response 9 (15.5%) 11 (21.2%)
Partial response 20 (34.5%) 25 (48.1%)
Stable disease 27 (46.6%) 13 (25%)
Local failure 2 (3.4%) 3 (5.8%)
FIGURE 2.  Follow-up after percutaneous cryoablation. Follow-up computed tomography (CT)-scans performed at 3 months 
(A and B), 6 months (C and D), and 1 year (E and F) after the cryoablation procedure showing a resorption of the ablation zone 
(same patient as Fig. 1).
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metastatic disease, among them six cryoablation procedures. 
One-year disease-specific survival and overall survival rates 
were 100% and 97.5%, respectively (Fig. 3).
Safety and Tolerance
Pneumothorax requiring chest tube placement 
occurred in 9 of the 48 procedures (18.8%), and chest tubes 
were removed after 1 day (n = 8) or 2 days (n = 1). CTCAE 
grade 3 adverse events within 30 days of the procedure 
occurred in 3 of 48 (6%) procedures including a delayed 
pneumothorax requiring pleurodesis, a thrombosis of a pre-
existing hemodialysis access arteriovenous fistula requiring 
thrombectomy, and a noncardiac chest pain, which sponta-
neously resolved. No grade 4 or 5 procedure-related adverse 
events occurred. No procedural-related delayed adverse 
events were observed. Hospital length of stay averaged 
1 day (range, 0–4 days) but varied based on differences of 
international standard practices.
There was no significant change of ECOG or KPS at 1, 
3, 6, or 12 months in comparison with baseline mean values. 
The SF-12 quality of life questionnaire revealed no clinically 
meaningful adverse impact on quality of life after cryoabla-
tion, though general health perception subscale showed sta-
tistical difference (63.9 versus 58.2 before cryoablation and at 
12-month follow-up, p = 0.047; Table 4)
DISCUSSION
We report the first prospective, multicenter study of 
image-guided percutaneous cryoablation for the treatment of 
lung metastases. In this study, we found 94.6% local tumor 
control rate at 12 months follow-up, associated with a well-
tolerated treatment.
A recent systematic review and a meta-analysis of 
patients with colorectal cancer lung metastases reported 
5-year overall survival rates of 27% to 68% after complete 
surgical resection.24,25
But today, although surgical resection remains the stan-
dard procedure for lung metastases and despite advances in 
surgical techniques, many patients with lung metastases are 
not surgical candidates because of comorbidities or intoler-
ance for further surgical resection. Percutaneous image-guided 
ablation offers the opportunity to treat nonsurgical candidates 
with limited tumor burden and preserve lung parenchyma for 
patients who have compromised respiratory function or who 
may need multiple interventions during the course of their 
disease management.5,9 For the latter reason, thorough accep-
tance of surgical metastasectomy has been tempered given 
that up to 50% of patients recur.26
The results of this trial compare favorably with the 
reported results utilizing other focal therapies including SBRT, 
RFA, microwave ablation, and cryoablation for the treatment 
of patients with metastatic lung disease.6,8,9,13,19 Okunieff et al.6 
reported 83% local control with SBRT at a median of 18.7 
months in the treatment of 50 patients with 125 tumors with 
a mean tumor diameter of 2.5 cm. Local control rate using 
RFA was 89% in a prospective study of 61 patients with meta-
static lung disease with a mean follow-up of 15 months9 and 
reported 4-year local efficacy 89% in a large prospective trial 
of 566 patients.8 Local control rate of 73.1% is reported in the 
treatment of 130 metastatic lung tumors with microwave abla-
tion with mean follow-up of 9 months.13 We have to acknowl-
edge that comparison of local control rates is difficult because 
this control rate depends on tumor diameter and location, even 
though the diameter of the tumors we treated in this prospec-
tive study (mean: 1.5 cm, range, 0.3–4.4) were within the 
range of what is described by other ablative techniques.8,27–29
Percutaneous cryoablation of lung and pleural tumors 
was well tolerated. The need for chest tube placement occurred 
in 18.8% of our procedures with 8 of 9 (89%) patients having 
the chest tube removed the day after the procedure. CTCAE 
grade 3 adverse events occurred in 6% of patients in this study, 
and no grade 4 or 5 adverse events. In addition, none of the 
patients undergoing cryoablation in this study experienced sig-
nificant pain reported as grade 2 or greater during the post-
procedural period. This low incidence of periprocedural and 
postprocedural pain has been widely recognized as one specific 
advantage of cryoablation over other thermal therapies.17,30–32
Cryoablation offers comparable, if not additional advan-
tages, when compared to radiofrequency and microwave abla-
tion. Current cryotechnology affords smaller (1.5 – 2.4 mm 
in diameter), more competitive, caliber cryoprobes compared 
with competing thermal modalities and segmental insulation 
for percutaneous application compared with early generation 
cryoprobes. In general, compared with the heat-based tech-
nologies, cryoablation treatment within the lung can be more 
easily monitored with CT imaging with the ablation zone 
defined by an interstitial infiltrate or low attenuation zone. A 
triple freeze–thaw cycle protocol was used in this study rather 
than the double freeze–thaw cycle more often used in kidney, 
liver, or soft tissue. This triple cycle exploits early focal edema 
and alveolar hemorrhage generated during the first thaw cycle 
resulting in better thermal conduction because of fluid beyond 
the margin of the targeted tumor.33 Niu et al.33 compared triple 
freeze–thaw cycle protocol (5-min freeze–5-min thaw–5-min 
freeze–5-min thaw–10-min freeze) and double freeze–thaw 
cycle protocol (10-min freeze–5-min thaw–10-min freeze) 
and concluded that triple freeze–thaw cycles may increase FIGURE 3.  Tumor size evolution graph during 1-year follow-up.
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ablation zone versus two freeze–thaw cycles and allow ear-
lier visualization or treatment-induced changes. Because of 
the low incidence of associated procedural pain, cryoablation 
can be comfortably performed under conscious sedation, even 
when ablating targeted tumors are within the chest wall or 
subpleural and juxtapleural lung close to somatically inner-
vated parietal pleura. Even for tumors within this location, 
cryoablation can be safely performed on tumors located in the 
lung periphery or involving the pleura with low risk for bron-
chopleural fistula.31
And finally, rapid involution in the size of the abla-
tion zone on CT imaging (Fig. 3) facilitates identification of 
local treatment failure with most local tumor progression, 
or incomplete ablation visualized by 6-month CT.5,34 In our 
study, 2 out of 3 local failures were detected on the 6-month 
evaluation.
Limitations of this study included a relatively small 
number of patients and a relatively short follow-up for assess-
ment of local tumor control. Nonetheless, these early results 
are certainly encouraging with intermediate and long-term 
data for trial participants still being collected and based on our 
experience from this trial an expanded more comprehensive 
study is currently enrolling patients. The patients included in 
the herein reported trial have mixed primary histology and 
cancer-specific survival cannot be compared with sufficient 
statistical power. In addition, follow-up imaging to assess 
local tumor control in this study utilized the structure and size 
of the ablation zone at 3-month imaging as a baseline for com-
parison with subsequent imaging, and not pretreatment tumor 
size as standard in RECIST and other oncologic evaluations. 
Regardless, this methodology has been successfully utilized 
to assess treatment response in prior ablation studies9 and in 
other applications of nonsurgical and nonsystemic local ener-
gies, specifically radiotherapy.
To summarize, and although percutaneous cryoablation 
for the treatment of lung metastases of 3.5 cm and smaller is 
safe and early local tumor control rates are promising and 
competitive with other contemporary technologies, large ran-
domized controlled trials are needed to compare local thera-
pies with the traditional standard surgical resection.35
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